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Abstract
Marek’s disease is a lymphoproliferative neoplastic disease of the chicken, which poses a serious threat to poultry health.
Marek’s disease virus (MDV)-induced T-cell lymphoma is also an excellent biomedical model for neoplasia research. Recently,
miRNAs have been demonstrated to play crucial roles in mediating neoplastic transformation. To investigate host miRNA
expression profiles in the tumor transformation phase of MDV infection, we performed deep sequencing in two MDV-
infected samples (tumorous spleen and MD lymphoma from liver), and two non-infected controls (non-infected spleen and
lymphocytes). In total, 187 and 16 known miRNAs were identified in chicken and MDV, respectively, and 17 novel chicken
miRNAs were further confirmed by qPCR. We identified 28 down-regulated miRNAs and 11 up-regulated miRNAs in MDV-
infected samples by bioinformatic analysis. Of nine further tested by qPCR, seven were verified. The gga-miR-181a, gga-miR-
26a, gga-miR-221, gga-miR-222, gga-miR-199*, and gga-miR-140* were down-regulated, and gga-miR-146c was up-
regulated in MDV-infected tumorous spleens and MD lymphomas. In addition, 189 putative target genes for seven
differentially expressed miRNAs were predicted. The luciferase reporter gene assay showed interactions of gga-miR-181a
with MYBL1, gga-miR-181a with IGF2BP3, and gga-miR-26a with EIF3A. Differential expression of miRNAs and the predicted
targets strongly suggest that they contribute to MDV-induced lymphomagenesis.
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Introduction
The miRNAs are small noncoding RNAs that act as a novel
species of gene regulators, playing important roles in multiple
biological processes, including growth, development, and differ-
entiation [1,2]. Generally, miRNAs negatively modulate gene
expression by reducing mRNA stability and interfering with
translation [3,4]. In addition to reports on the direct role of
miRNAs on protein-encoding genes, there are increasing numbers
of recent studies on miRNA and cancer. Many miRNAs are
aberrantly expressed in cancers. Some miRNAs act as oncogenes,
while others show tumor suppressor activities [5,6]. miRNAs
mediate neoplastic transformation [7], and are strongly linked to
lymphoma development in hematologic malignancies [8–10]. The
profiling of miRNA expression is a useful tool for classifying
various types of tumors by developmental lineage and differenti-
ation state [11]. Recently, miRNAs were reported to be involved
in virus-induced, in addition to non-infectious, forms of cancer
[12,13]. Oncogenic viruses have been implicated in a large
proportion of neoplasms in animals, and they play key roles in
molecular pathways of neoplastic transformation.
Marek’s disease (MD) is a highly contagious, lymphotropic,
neoplastic disease. Although vaccines have been used since 1972,
MD remains a serious threat to poultry health due to the
increasing virulence of MDV under the pressure of vaccines [14].
Marek’s disease virus (MDV) induced MD lymphoma, a natural
and rapid-onset T-cell lymphoma, is also an excellent biomedical
model for virus-induced lymphoma [15,16]. Recently, studies on
host and virus miRNAs in the MD model system have been
reported [17–23]. Burnside et al. (2008) identified miRNAs in
MDV-infected chicken embryo fibroblasts (CEF) using deep
sequencing technology [18]. In their study, 125463 high quality
reads showed exact matches to the chicken genome, and 63
novel miRNA candidates were identified. Some host miRNAs,
including gga-miR-let-7, gga-miR-199a-1, gga-miR-26a, gga-
miR-181a, and gga-miR-16, were expressed at lower levels in
MDV-induced tumors than non-infected spleens, indicating their
potential importance in tumorigenesis. Yao et al. [21] investigat-
ed miRNA expression profiles in seven MDV-transformed cell
lines by using microarray. Their study showed that several host-
encoded miRNAs, including gga-miR-155, gga-miR-150, gga-
miR-451, gga-miR-26a, and gga-miR-223, were down-regulated
in all MDV-transformed cell lines compared to normal
splenocytes, and nine MDV-1-encoded miRNAs were up-
regulated in all of the MDV-transformed cell lines compared
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to the MDV-negative reticuloendotheliosis virus (REV)-T-trans-
formed cell line AVOL-1.
Previous studies have mainly focused on miRNA profiles of
MDV-infected CEF and MDV-transformed cell lines and
expression of several individual miRNAs in MDV-induced
splenic tumors. To date, there have been no reports of
comprehensive miRNA expression profiles in lymphoma induced
by MDV. Deep sequencing technology, with its high sensitivity,
is highly suited for small RNA discovery [18,24]. In the current
study, we performed Solexa deep sequencing of MDV-infected
and non-infected samples, including MDV-infected whole spleen
(tumorous spleen) containing both tumor and non-tumor tissue,
lymphoma isolated from MDV-infected liver, non-infected
spleen, and non-infected peripheral blood lymphocytes, to
elucidate repertoires of host and virus miRNAs. Our objective
was to characterize miRNA involvement in pathophysiological
processes of tumor transformation.
Results
Overview for Deep Sequencing
Raw data was processed as described in the Materials and
Methods section. The overview of distribution of count
percentage and numbers, from raw data to cleaned sequences,
is shown in Table 1. MDV-infected tumorous spleen and
MDV-induced lymphoma from liver were enriched in mRNA,
RFam, and Repbase (13.88% and 12.81% by counts, respec-
tively) compared to non-infected spleen and lymphocytes (2.61%
and 2.12% by counts, respectively). Based upon the alignment
results (see Materials and Methods for details), sequences were
classified into known miRNAs and three groups of novel
miRNA candidates. Subgroup1, which we considered novel 5p-
or 3p-derived miRNA candidates, contains sequences mapped
to the 5p or 3p arm of the pre-miRNA hairpin opposite to the
annotated mature miRNA-containing arm. Subgroup2 includes
miRNA candidates mapped to vertebrate or herpesvirus (except
chicken or MDV) precursor miRNAs. Subgroup3 includes
miRNA candidates not mapped to vertebrate or herpesvirus
miRNA precursor, but mapped to the chicken or MDV
genomes; and the extended genome sequences forming hairpins.
The number of known miRNAs and novel miRNA candidates
is listed in Table 2. The size distribution was analyzed and was
not significantly different in the four libraries. The majority of
the reads were 21–23 nt, with 22 nt as the most frequent size
(Figure 1).
isomiRs of Known miRNAs and the Expression Patterns of
miRNA and miRNA*s
In total, 187 known chicken miRNAs were identified. Among
them, 165 were in MDV-infected samples, 174 were in non-
infected samples, and 117 were identified in all four samples.
Three miRNAs (gga-miR-135a, gga-miR-375, and gga-miR-429)
were uniquely detected in MDV-infected samples, and three
miRNAs, (gga-miR-1728-3p, gga-miR-1729*, and gga-miR-3530)
were uniquely detected in non-infected samples. Additionally, 16
known MDV miRNAs were detected in both tumorous spleen and
MD lymphoma from liver. Identified known chicken and MDV
miRNAs are listed in Table S1. As previously reported [24–26],
the present study identified many variants for known miRNAs,
especially at the 39 and 59ends. These variants were defined as
‘‘isomiRs’’, which frequently had higher counts than the corre-
sponding known reference miRNA sequences listed in miRBase.
The most abundant sequence in alignment with known chicken
miRNAs listed in miRBase 16.0 was identified as a representative
of the alignment and designated the ‘‘dominant isomiR’’. The
dominant isomiR was further defined based upon its differences
from the reference miRNA sequence in miRBase 16.0. For
example, gga-miR-1306_L-3R+2 (L= 59end; R= 39end) is a
variant of gga-miR-1306 and is 3 nt shorter at 59 end and 2 nt
longer at 39 end than gga-miR-1306. gga-miR-1579_21GA
contains a variation from G to A at the 21st nucleotide compared
with the reference gga-miR-1579. In total, isomiRs of 116 known
chicken miRNAs, including 82 in tumorous spleen, 69 in MD
lymphoma, 70 in non-infected spleen, and 82 in non-infected
lymphocytes, had more counts than reference miRNA sequences
listed in miRBase 16.0. Details of isomiRs for each known miRNA
are presented in Table S2, with sequences perfectly matched with
reference pre-miRNAs listed at the top, followed by one-error
alignments.
In addition, we characterized the counts of 46 mature miRNAs
derived from the two arms of 23 precursor miRNAs (Table 3). Of
them, 15 miRNAs originating from the 59 (5p) ends had more
counts than those originating from 39 (3p) ends. Three 3p-derived
miRNAs (gga-miR-199-3p, gga-miR-22-3p, and gga-miR-140-3p)
had more counts than their corresponding 5p-derived miRNAs.
Four precursor miRNAs (gga-mir-126, gga-mir-1728, gga-mir-
301b, and gga-mir-455) showed a reversal in the ratios of the 5p-
and 3p- derived sequences across the four RNA libraries.
Novel miRNA Candidate Identification
There were 68, 155, and 703 chicken miRNA candidates in
subgroup1, 2, and 3, respectively (Table S3). One MDV
miRNA candidates in each of subgroup1 and subgroup3 was
identified. In the present study, 42 of 68 novel miRNA
candidates in subgroup1 were new 3p-derived sequences, and
26 were new 5p-derived sequences. Of the 68 candidates (Table
S3), 40 miRNA candidates were mapped to other vertebrate
known mature miRNAs and 41 were detected previously by
Glazov et al. [24]. As expected, the counts of known mature
miRNAs were usually much higher than their corresponding
novel miRNA* (star) candidates, and only eight novel candi-
dates showed higher counts than the annotated known mature
miRNAs in at least one library (Table S4). The results are
consistent with the known mechanisms of miRNA biogenesis
and strand preference. A small RNA duplex is generated from a
hairpin-like miRNA precursor. The strand with lower thermo-
dynamic stability at its 59 end is more easily incorporated into
the RISC complex, and the other inactive strand, called
miRNA* (star) is rapidly degraded [27]. Usually, miRNA*
cannot be detected by conventional methods due to their rapid
turnover; however, the high sensitivity of deep sequencing
allows their identification.
Verification of Novel miRNAs
To further verify novel miRNAs in the four samples, we
produced customized miRNA arrays including 533 novel
miRNA candidate probes (Table S5). In total, 276 out of 533
probes were detectable. There were 18, 74, and 184 miRNA
candidates in subgroup1, 2, and 3, respectively, detected in
microarrays. The microarray signals and Solexa deep sequenc-
ing counts for the 276 detectable probes are listed in Table S6.
Of the 276 detectable probes, 17 novel miRNA candidates with
counts ranged from 1 to 11374 (Table S7), including 11
candidates from subgroup2, and six from subgroup3 were
further verified by qPCR and amplicons were cloned into
pMD-19T plasmid and sequenced (Figure S1).
Analysis of miRNA Transcriptome in Lymphoma
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Differential Expression Analysis of Known miRNAs
between MDV-infected and Non-infected Samples
Differential expression of miRNAs between MDV-infected and
non-infected samples based on counts was conducted using a web
tool, IDEG6 [28]. Because the perfect-match isomiRs might not
be the unique functional isoform [29], counts from different
isoforms of the same miRNA were pooled. Non-infected spleen
was used as the control to identify differentially expressed miRNAs
in tumorous spleen (Table S8). Because the liver tumor was a
lymphocytic solid tumor, consisting of a heterogeneious mixture of
Figure 1. Size distribution of known miRNAs and novel miRNA candidates.
doi:10.1371/journal.pone.0051003.g001
Table 1. Overview of reads from raw data to cleaned sequences.
MDV-infected Non-infected
RNA class % average Tumorous spleen
Lymphoma
(liver tumor) Spleen
Lymphocytes
(peripheral blood)
# counts % # counts % # counts % # counts %
Raw data \ 7,764,498 100% 6,356,397 100% 6,362,545 100% 7,596,330 100%
Adapter dimer filtera 0.48 76,808 0.99 42,924 0.68 3,715 0.06 15,123 0.2
Junk filterb 1.01 26,945 0.35 23,507 0.37 196,229 3.08 16,743 0.22
Length filterc 5.98 801,493 10.32 460,394 7.24 238,932 3.76 196,453 2.59
Simple sequence filterd 0.07 8,646 0.11 5,976 0.09 1,840 0.03 3,708 0.05
Copy#,3 5.48 719,700 9.27 346,675 5.45 198,874 3.13 308,433 4.06
mRNA,RFam,Repbasee 7.86 1,077,754 13.88 814,183 12.81 165,784 2.61 161,361 2.12
mRNAf 0.22 39,164 0.50 16,057 0.25 2,783 0.04 5,189 0.07
rRNAg 2.90 390,752 5.03 317,444 4.99 76,257 1.20 28,290 0.37
tRNAg 0.73 102,413 1.32 54,516 0.86 13,871 0.22 41,056 0.54
snRNAg 0.54 48,209 0.62 93,853 1.48 2,003 0.03 2,205 0.03
snoRNAg 0.17 22,641 0.29 9,178 0.14 2,936 0.05 13,480 0.18
Repeatsh 5.34 799,335 10.29 495,391 7.79 117,624 1.85 106,753 1.41
Cleaned sequences 79.14 5,053,152 65.1 4,662,738 73.4 5,557,171 87.34 6,894,509 90.76
aAdapter dimer: 59 ADT, 39 ADT & 59 ADT and 39ADT joined together without insertion.
bJunk sequence: 80% of A, or C, or G, or T, or 3N; 10 repeats of dimer, 6 repeats of trimer, or 5 repeats of tetramer; 7 consecutive A, 8 consecutive C, 6 consecutive G or 7
consecutive T; contained only A and C or only G and T.
cSequences with length ,16 nt or .26 nt were removed.
dSimple sequence: sequence with more than 80% of A, or C, or G, or T, or 3N in it.
eSequences passing mRNA, RFam, Repbase filter.
fmRNA: ftp://hgdownload.cse.ucsc.edu/goldenPath/galGal2/bigZips/.
gRfam(V9.1): ftp://ftp.sanger.ac.uk/pub/databases/Rfam/9.1/.
hrepeat-repbase (V15.13): http://www.girinst.org/repbase/update/index.html.
Note: There is overlap in mapping of reads with mRNA, rRNA, tRNA, snRNA, snoRNA and repeats.
doi:10.1371/journal.pone.0051003.t001
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oncogenic, inflammatory, and immunologically active and inactive
cells [30], both the non-infected spleen and non-infected
lymphocytes were used as controls to identify differentially
expressed miRNAs in the MD lymphoma from liver (Table S9).
There were 94 and 63 miRNAs deregulated in tumorous spleen
and MD lymphoma compared with their corresponding controls.
The differentially expressed miRNAs that occurred in both
tumorous spleen and MD lymphoma from liver were considered
as deregulated miRNAs in MDV-infected samples during tumor
transformation. In total, 11 up-regulated and 28 down-regulated
miRNAs in MDV-infected samples were identified (Table S10). Of
these 39 miRNAs, four down-regulated miRNAs (gga-miR-221,
2140*, 2199*, and 181a) and four up-regulated miRNAs (gga-
miR-146c, 2146b, 2222, and 2155) in the two MDV-infected
samples with high counts were selected to be further verified by
qPCR among MDV-infected whole spleens with tumors (tumor-
ous spleens), MD lymphomas from liver, and non-infected spleens.
Additionally, because of previous reports on gga-miR-26a
Table 2. Number of known chicken miRNAs and novel miRNA candidates in four samples.
MDV infected Non-infected
Group Tumorous spleen
Lymphoma
(liver tumor) Spleen
Lymphocytes (peripheral
blood)
Known miRNAs 160 138 143 159
Novel miRNA candidates in subgroup1 44 38 42 61
Novel miRNA candidates in subgroup2 96 86 81 113
Novel miRNA candidates in subgroup3 498 142 71 231
doi:10.1371/journal.pone.0051003.t002
Table 3. Counts of known miRNAs originating from 59 or 39 arm of precursors in four libraries.
MDV-infected Non-infected
Tumorous spleen
Lymphoma
(liver tumor) Spleen
Lymphocytes
(peripheral blood)
Index Pre-miRNA 5p 3p 5p 3p 5p 3p 5p 3p
1 gga-mir-181a 6294a 271 4725 78 23970 238 55572 1297
2 gga-mir-142 9417 2495 5752 866 9915 610 38470 15528
3 gga-mir-10a 7733 90 869 4 8317 271 416 -
4 gga-mir-146b 11348 85 25346 57 4703 14 15407 65
5 gga-mir-99a 1876 37 955 41 3359 78 17989 298
6 gga-mir-146c 31407 594 99065 721 2432 25 16804 193
7b gga-mir-126 612 906 110 139 1349 1095 671 337
8 gga-mir-17 877 398 493 280 1133 446 3396 1432
9 gga-mir-1456 224 7 80 – 106 – 606 5
10 gga-mir-1729 55 – 11 – 105 10 381 102
11 gga-mir-15c 401 4 123 – 102 – 2283 27
12 gga-mir-1329 42 5 42 – 23 – 289 13
13 gga-mir-1552 21 5 3 – 10 6 95 24
14 gga-mir-1551 20 3 17 3 8 – 38 4
15 gga-mir-1451 20 16 11 – 6 – 61 47
16 gga-mir-1736 – – – – – – 3 3
17b gga-mir-1728 – – 4 – – 3 18 6
18b gga-mir-301b 27 18 20 3 3 24 245 121
19c gga-mir-199 284 61748 64 13939 948 243757 74 23853
20c gga-mir-22 96 1818 19 497 87 1755 238 5951
21c gga-mir-140 43 45110 14 24393 57 52749 277 220818
22b gga-mir-455 48 65 6 3 20 45 - -
23 gga-mir-30a 4994 381 2736 85 7650 675 7297 561
a. Numbers indicate counts for all isomiRs originating from 59(5p) or 39(3p) arms of the miRNA precursor.
b. miRNAs from two arms showed a reversal in the ratios across four RNA libraries.
c. miRNAs deriving from 39 ends of precursor had more counts than that from 59 ends.
doi:10.1371/journal.pone.0051003.t003
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[18,21,23], it was also chosen to be verified by qPCR, which
showed down-regulation in MD lymphoma from liver compared
with non-infected lymphocytes and non-infected spleen in the
current study (Table S9). The differential expression profiles of
seven miRNAs (gga-miR-221, 2140*,2199*, 181a, 2146b,
2146c, and 226a) were consistent between IDEG6 analysis and
qPCR. gga-miR-181a, gga-miR-26a, gga-miR-221, gga-miR-
199*, and gga-miR-140* were down-regulated (Figure 2A–E).
gga-miR-146b showed a trend toward being higher, and gga-miR-
146c was up-regulated in tumorous spleen and MD lymphoma
compared to non-infected spleens (Figure 2F, G). Only two
miRNAs (gga-miR-155 and 2222) showed different results from
the two methods. gga-miR-155 was up-regulated in two MDV-
infected samples in IDEG6 analysis, but it showed a trend toward
down-regulation (p.0.05) in MDV-infected compared to non-
infected samples by qPCR (Figure 2H). gga-miR-222 was up-
regulated in MDV-infected samples in IDEG6 analysis; however,
it was down-regulated in MD lymphoma from liver (not MDV-
infected spleen) compared to non-infected spleen by qPCR
(Figure 2I).
Prediction of Potential Targets for Nine Known miRNAs
Putative target genes of gga-miR-181a, gga-miR-26a, gga-miR-
221, gga-miR-222, gga-miR-155, gga-miR-146b, and gga-miR-
146c were predicted by TargetScan (Version 6.0) [31]. Target
genes of gga-miR-199* and gga-miR-140*, for which whose seed
sequences could not be found in TargetScan, were predicted by
TargetScanHuman Custom (Version 5.3). In total, 1598 annotat-
ed mRNA transcripts were predicted (Table S11). Because
negatively correlated expression patterns between miRNAs and
their corresponding targets have been reported [32], we used
differentially expressed genes in tumorous spleens versus non-
infected spleens from our previous microarry study on gene
expression [33] to narrow down candidate targets. The genes
presenting inverse expression patterns compared to their corre-
sponding miRNAs were selected. In total, 189 candidate targets
which were deregulated in tumorous spleens in the previous study
were identified (Table S12). To investigate interactions of miRNAs
and targets, and also interaction of targets and targets, the protein-
protein interactions from STRING were extracted, and network
was drawn (Figure 3). Only one target gene for miR-26a, EZH2
was reported previously [34]. All other interactions of miRNAs
and targets were proposed for the first time in this study, and can
now be considered as candidates for further research.
Target Validation using Luciferase Reporter Gene Assays
To further verify the interaction of predicted target genes and
miRNAs, we conducted luciferase reporter gene assays to detect
interaction of gga-miR-181a withMYBL1 and IGF2BP3, gga-miR-
26a with EIF3A, and gga-miR-221 with BCL11B. The pmiR-RB-
REPORT-UTR and pmiR-RB-REPORT-mutated UTR were
transfected into 293 T cells with miRNA mimic or negative
control (Figure 4). The luciferase activity was significantly reduced,
by 33%, when a gga-miR-181a mimic was co-transfected with
pmiR-RB-REPORT-MYBL1UTR into 293T cells, suggesting
that significant interaction occurs between them (Figure 5A).
Transfection of the gga-miR-181a mimic also inhibited luciferase
activity of pmiR-RB-REPORT-IGF2BP3 UTR by 27%
(Figure 5B). The gga-miR-26a mimic inhibited luciferase activity
of pmiR-RB-REPORT-EIF3A UTR by 24% (Figure 5C). The
gga-miR-221 mimic slightly decreased luciferase activity of pmiR-
RB-REPORT-BCL11B UTR by 12% (Figure 5D). These results
demonstrate significant interaction of gga-miR-181a with MYBL1
and IGF2BP3, and of gga-miR-26a with EIF3A.
Discussion
In this study, two MDV-infected samples (tumorous spleen and
MD lymphoma from liver) were selected for analysis. They
represented two types of visceral tumors that frequently occur after
MDV infection. Typically, very tiny tumor nodules appeared
throughout the spleen in the current study and they could not be
reliably dissected free from adjacent splenic tissue; therefore, whole
spleens including the tumors (termed, tumorous spleens) were
harvested for analysis. However, MDV-induced tumors in the liver
were large and mature tumors and, thus, could be dissected free
from adjacent non-tumor tissue and harvested. Generally, MD
tumors are characterized by lymphocyte infiltration. Lymphoma-
tous lesions in visceral organs are proliferative, consisting of
proliferating small to medium lymphocytes, lymphoblasts, and
activated and primitive reticulum cells [30]. In MD lymphomas
from liver, although residual liver cell-derived miRNAs may
contribute to the results, the contribution of hepatocytes is
expected to be far less than that of the much greater numbers of
infiltrating lymphocytes. Considering the cellular and lymphocytic
properties of the selected MDV-induced tumor tissues, non-
infected whole spleen and lymphocytes from peripheral blood
were chosen as the two controls in deep sequencing.
We found that MDV-infected samples had higher percentages
than non-infected samples in mRNA, RFam, and repbase
categories, which indicates that these known RNA species were
activated during MDV infection and might play important roles in
MDV-related pathology. In addition, isomiRs were very common,
and many isomiRs had more counts than the corresponding
miRNA sequences listed in miRBase. They could, therefore, be
considered for use as reference sequence under pathological
conditions of MDV infection. In addition, differential expression
of miRNA counts was analyzed by IDEG6. Because of the lack of
biological replicates and technical duplicates in sequencing, a very
stringent p-value cut-off (P,0.001 simultaneously in Audic-
Claverie test, Fisher exact test, and Chi-squared 262 test with
the Bonferroni correction to adjust for pair-wise comparison) was
applied to identify differentially expressed miRNAs [35,36].
Moreover, differentially expressed miRNAs occurring in both of
the two comparison groups, (MDV-infected tumorous spleen vs.
non-infected spleen, and MD lymphoma vs. non-infected spleen/
lymphocytes) were considered to be deregulated miRNAs in MD
tumors compared to non-infected controls. Only 11 up-regulated
and 28 down-regulated miRNAs were identified. The relatively
small number of deregulated miRNAs might result from the
conservative statistical thresholds used in differential expression
analysis. Subsequently, differential expression of nine miRNAs was
further investigated by qPCR, and seven were verified.
In the current study, miR-181a and miR-26a were down-
regulated in tumorous spleen and MD lymphoma, compared to
non-infected spleen. Several previous studies provide evidence of
their involvement in cancer. Two members of miR-181 (miR-
181a, 181b) were down-regulated in glioma specimens and
glioma cell lines [37], as well as pituitary adenomas [38] and
lymphocytic leukemia [39]. It has been suggested that suppres-
sion of miRNA-181a may increase cell growth in the lung
carcinoma cell line, A549 [40]. The expression of miR-181a,b
was also decreased in avian influenza virus (AIV)-infected
chicken lungs and tracheae, and they were proposed as strong
miRNA candidates for regulating host response to AIV infection
[41]. Acting as a tumor suppressor, miR-181a triggered growth
inhibition, induced apoptosis, and blocked invasion in glioma
cells. Deregulation of miR-181a may be a critical factor for
malignancy occurrence in human gliomas [42]. The luciferase
Analysis of miRNA Transcriptome in Lymphoma
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reporter gene assay indicated significant interaction of miR-181a
with two predicted target genes, MYBL1 and IGF2BP3. MYBL1
acting as an oncogene, was associated with tumorigenesis [43],
and its expression was elevated in human cancers [44,45].
IGF2BP3 is considered to be the first biomarker of prognostic
significance in ovarian clear cell carcinoma [46]. Its expression
has been observed in many malignant neoplasms, including
cervical carcinomas [47] and pancreatic ductal adenocarcinoma
tissues [48]. The gene expression of MYBL1 and IGF2BP3 was
up-regulated in tumorous spleen in our previous microarray
study [33]. Their up-regulation in tumorous spleen might result
from down-regulation of miR-181a.
miR-26a is considered to be a potential tumor suppressor [49].
Suppression of miR-26a has been demonstrated in various human
cancers, such as thyroid anaplastic carcinoma [50] and Burkitt’s
lymphoma [34,50–52]. A recent miRNA microarray study has
shown that miR-26a was down-regulated in nasopharyngeal
carcinoma (NPC) tissues compared with adjacent normal tissues
[53]. Chen et al. showed that miR-26a inhibited cell growth and
colony formation, induced a G1 arrest in NPC cells, and
suppressed tumorigenesis in a murine model of NPC xenograft
[53]. In addition, miR-26a was also down-regulated in seven
independently-derived MDV-transformed lymphoblastoid T cell
lines, and ALV and REV transformed lymphoid cell lines [21]. As
Figure 2. Expression of nine chicken known miRNAs. A. Expression of gga-miR-181a among TS, LL, and NS. B. Expression of gga-miR-26a
among TS, LL, and NS. C. Expression of gga-miR-221 among TS, LL, and NS. D. Expression of gga-miR-222 among TS, LL, and NS. E. The expression of
gga-miR-199* among TS, LL, and NS. F. Expression of gga-miR-140* among TS, LL, and NS. G. The expression of gga-miR-155 among TS, LL, and NS. H.
Expression of gga-miR-146b. I. Expression of gga-miR-146c among TS, LL, and NS. TS: MDV-infected tumorous spleen; LL: MD lymphoma from liver;
NS: non-infected spleen.
doi:10.1371/journal.pone.0051003.g002
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the only known target gene of miR-26a, EZH2, acting as an
oncogene, was shown to be involved in proliferation of different
cell types, including tumor cell lines [54]; it showed oncogenic
activity and tumor transformation requiring histone methylatrans-
ferase activity. EZH2 has been detected in a variety of neoplastic
cells of poorly differentiated invasive carcinomas [55]. Its catalytic
activity was shown to be essential for oncogenic transformation
[54]. EIF3A, another predicted target gene of miR-26a was up-
regulated in tumorous spleen of our previous study [33].
Overexpression of EIF3A occurs in many solid tumors and cancer
cell lines including human breast [56], cervical [57], esophageal
[58], lung [59], gastric cancers [58] and Hela cells [59]. It is
regarded as prognostic biomarker for poor clinical outcome [60].
Significant interaction of miR-26a and EIF3A was verified in the
current study by using the luciferase reporter gene assay, which
indicated that down-regulation of miR-26a could induce expres-
sion of EIF3A in MD lymphoma.
miR-221 and miR-222 are considered to be potentially
oncogenic miRNAs. They are involved in tumorigenesis and
affect the expression of cell cycle regulatory proteins in different
human cancers [61,62]. The regulation of miR-221 in different
cancer types appears to be variable. Both miR-221 and miR-
222 were over-expressed in tumors of the lung, breast, pancreas
and in glioblastoma, and papillary thyroid carcinoma, [37,63–
66]. However, their expression in prostate cancer and chronic
lymphocytic leukemia was down-regulated [1,10,67]. The same
discrepancy has been reported in MDV-transformed samples.
Up-regulation of miR-221 and miR-222 was observed in MSB1
[22,23,61]. However, the increased expression was unique to
the MSB1 cell line, while in some other MDV transformed cell
lines, such as MDCC-226S (T226S) and MDCC-265L (T265L),
levels of miR-221 and miR-222 were unchanged or down-
regulated [61]. The results may be due to dissimilarities among
these cell lines, with MSB1 being infected by BC1, while T226S
and T265 are derived from a lymphoma infected by RB1B,
which is more lymphomagenic than BC1 [61]. In the current
study, expression of miR-221 and miR-222 was down-regulated
in MDV-infected samples, especially in MD lymphoma, which
was consistent with a previous report that miR-221 was slightly
down-regulated in MDV-induced splenic tumors [18].
Differential expression of miR-199* and miR-140* in MDV-
infected samples was reported here for the first time. Both were
down-regulated in tumorous spleens and MD lymphoma. To our
knowledge, this is the first report of involvement of miR-140* in
tumors. Its significant down-regulation in the current study
strongly implicates involvement of miR-140* in oncogenic
transformation. There are limited reports about the function of
miR-199* in cancer. Murakami et al. reported that miR-199 and
miR-199* were down-regulated in hepatocellular carcinoma
compared with adjacent non-tumorous tissue [68]. The down-
regulation of miR-199* in MDV-infected samples indicates its
role in tumorigenesis.
Some predicted target genes for miR-221, 222, and 199*, such
as RUNX2, BCL11B, and RAB1A, show oncogenic characteristics
Figure 3. Network of differentially expressed miRNAs and their putative targets. In the network, miRNAs are represented by yellow circles
and targets are represented by blue nodes. Solid lines show target-target interactions; dashed lines show miRNA-target interactions.
doi:10.1371/journal.pone.0051003.g003
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in tumors. BCL11B, as a predicted target for miR-221 and miR-
199*, has been implicated in T-cell development, differentiation,
and proliferation [69]. Its overexpression was detected primarily in
T-cell malignancies, which was a characteristic feature of T-cell
acute lymphoblastic leukemia (T-ALL) [70]. Our previous
microarray results showed it was up-regulated in tumorous spleen
[33]. However, the luciferase reporter gene assay showed only
slight interaction between miR-221 and BCL11B. Although
BCL11B is likely not the target gene of miR-221, its involvement
in tumorigenesis is still suggested because of its up-regulation in
MD tumors.
The differential expression of miR-146b and miR-146c between
MDV-infected and non-infected samples was analyzed. In the
current study, miR-146b showed an increasing trend, and miR-
146c was significantly up-regulated in tumorous spleens and MD
lymphomas compared to non-infected spleens. In humans,
elevated expression of miR-146b was observed in malignant
myoepithelioma of breast [71] as well as papillary thyroid
carcinoma [63,72]. Nikiforova et al. reported that miR-146b was
overexpressed at least 2-fold in papillary thyroid cancer compared
with benign hyperplastic nodules [73]. In our study, miR-146b
only showed an increasing trend, whereas its isoform, miR-146c,
which has been only reported in chicken and zebra finch to date,
showed significantly elevated expression level in tumorous spleen
and MD lymphoma. Although the specific function of miR-146c
and its predicted target gene are unknown, the elevated expression
of miR-146c in MDV-induced tumor indicates its important role
in lymphomagenesis.
Conclusion
Solexa deep sequencing is an effective high-throughput
approach to investigate the miRNA repertoire. In this study, 187
known chicken and 16 MDV miRNAs were identified, and 17
novel miRNA candidates were confirmed by qPCR. Abundant
isomiRs were detected; therefore, they can be utilized to refine the
miRNA annotation in miRBase. Six miRNAs (gga-miR-181a,
gga-miR-26a, gga-miR-221, gga-miR-222, gga-miR-199*, and
gga-miR-140*) were down-regulated and one miRNA (miR-146c)
was up-regulated in MDV-infected samples, and especially in MD
lymphomas, compared to non-infected samples. Interactions of
miRNAs and predicted target genes, including gga-miR-181a with
MYBL1 and IGF2BP3, and gga-miR-26a with EIF3A, were
discovered by using the luciferase reporter gene assay. Collectively,
differential expression of miRNAs and target genes in MD
lymphoma strongly suggests that they are involved in MDV-
induced lymphoma transformation and they facilitate neoplastic
transformation.
Materials and Methods
Sample Collection
Chickens from a White Leghorn specific pathogen free line
(BWEL) [74] were used. One hundred randomly selected chickens
were infected intraperitoneally at one day of age with 2000 PFU of
the MDV GA strain (passage 9) and the remaining 50 chickens
were injected with the same dosage of diluent (0.2 mL) as controls.
The two groups were kept in separate isolators in different rooms.
The trial period lasted to 56 days postinfection (d.p.i.). During this
Figure 4. Schema of miRNA binding sites in corresponding 39-UTR sequence of chicken predicated target gene (seed sequence
highlighted in red). A. Schema of binding site for gga-miR-181a and MYBL1; B. Schema of binding site for gga-miR-181a and IGF2BP3; C. Schema of
binding site for gga-miR-26a and EIF3A; D. Schema of binding site for gga-miR-221 and BCL11B. Arrow points to mutated target gene 39-UTR
eliminating the seed binding site.
doi:10.1371/journal.pone.0051003.g004
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phase, the chickens’ clinical signs were observed 2–3 times daily
and severely morbid birds were euthanized. Whole spleens with
small tumors were removed, and MDV-induced tumors in liver
were dissected from adjacent non-tumor tissue and harvested.
Whole spleens and lymphocytes from peripheral blood were
harvested from age- and sex-matched non-infected birds, to serve
as sources of control tissue. Animal experiments were approved by
the Animal Care and Use Committee of China Agricultural
University (Approval ID: XXCB-20090209) and the experiment
was performed according to regulations and guidelines established
by this committee. All tissues and lymphocytes were immediately
stored in RNAfixer (BioTeke Co., Ltd, Beijing, China) at 4uC
overnight and then transferred to 280uC until RNA isolation.
Four samples (MDV-infected whole spleen, MD liver lymphoma,
non-infected spleen, and non-infected lymphocytes) were used to
perform high-throughput Solexa deep sequencing. The whole
spleen with tumors and the MD lymphoma from liver were from
the same MDV-infected chicken at 46 d.p.i.; the non-infected
spleen was collected at 40 d.p.i., and the lymphocytes were from
two chickens at 40 d.p.i. In addition, eight tumorous spleens
(whole spleens including tumor and adjacent non-tumor tissue),
eight MD liver lymphomas (dissected from adjacent non-tumor
tissue), and eight non-infected whole spleens were harvested to
detect differential expression of miRNAs (Table 4).
Total RNA Isolation, Small RNA Library Construction and
Deep Sequencing
Total RNA of the individual four samples was extracted using
the mirVana miRNA Isolation Kit (Ambion, Austin, USA)
according to the manufacturer’s protocol. Briefly, 10 mg of RNA
Figure 5. Target validation using luciferase reporter assays. A. Interaction validation for gga-miR-181a and MYBL1. B. Interaction validation
for gga-miR-181a and IGF2BP3. C. Interaction validation for gga-miR-26a and EIF3A. D. Interaction validation for gga-miR-221 and BCL11B. 293T cells
were co-transfected with pmiR-RB-REPOR-UTR, or pmiR-RB-REPOR-mutated UTR and miRNA mimic, or negative control. Gene-wtUTR: wild type 39UTR
of predicted target gene. Gene-mutUTR: Mutated 39UTR of predicted target gene. NC: Negative control.
doi:10.1371/journal.pone.0051003.g005
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sample was size fractionated with a YM-100 column (Millipore).
The larger RNA fraction (.100 KDa) was removed. The smaller
RNA fraction (,100KDa) was further fractioned on a 15% tris-
borate-EDTA (TBE) urea polyacrylamide gel and the 15–50 nt
fraction was obtained. Subsequently, 59 and 39 RNA adapters
were ligated to the small RNA by T4 RNA ligase (Promega),
followed by reverse transcription and PCR product purification.
Purified products were quantified on the TBS-380 mini-fluorom-
eter (Turner Biosystems) using PicogreenH dsDNA quantitation
reagent (Invitrogen), then diluted to 10 nM and transferred for
sequencing on the Illumina/Solexa G1 sequencer (Illumina, San
Diego, USA ). Deep sequencing data has been deposited in
NCBI’s Gene expression Omnibus (GEO). The accession numbers
are: Series, GSE31349; Samples, GSM777474-GSM777477.
Data Processing
Data processing followed the procedures as described in a
previous study [75]. Briefly, the raw reads were subjected to the
Illumina pipeline filter (Solexa 0.3), and then the dataset was
further processed with an in-house program, ACGT101-miR (LC
Sciences, Houston, Texas, USA) [75–77] to remove adapter
dimers, junk, low complexity, low copy (Copy # ,3) reads,
common RNA families (mRNA, rRNA, tRNA, snRNA, snoRNA)
and repeats. Subsequently, unique sequences were mapped to
chicken or MDV precursors in miRBase 16.0 by BLASTn search
to identify known miRNAs and novel 3p- and 5p- derived
miRNAs. Length variation at both 39 and 59 ends and one
mismatch inside of the sequence were allowed in the alignment.
The unique sequences mapping to chicken or MDV mature
miRNAs in hairpin arms were identified as known miRNAs. The
unique sequences mapping to the other arm of known chicken or
MDV precursor hairpin opposite to the annotated mature
miRNA-containing arm were considered to be novel 5p- or 3p-
derived miRNA candidates. The remaining sequences were
mapped to other vertebrate or herpesvirus precursors (with the
exclusion of chicken and MDV) in miRBase 16.0 by BLASTn
search, and the mapped pre-miRNAs were further BLASTed
against the chicken and MDV genomes to determine their
genomic locations. The unmapped sequences were BLASTed
against the chicken and MDV genomes, and the hairpin RNA
structures containing sequences were predicated from the flank
60 nt sequences using RNAfold software (http://rna.tbi.univie.ac.
at/cgi-bin/RNAfold.cgi). The criteria for secondary structure
prediction [73] were: (1) number of base pairs in a stem $16 bp;
(2) number of allowed errors #18; (3) free energy (DG) #
215 kCal mol-1; (4) percentage of miRNA appearing in the stem
$80%; (5) length of hairpin$53 nts; and (6) length of hairpin
loop#22 nts.
Microarray Analysis
To confirm results of deep sequencing, we performed micro-
array analysis with customized probes, which were produced by a
service provider (LC Sciences, Houston, USA). Briefly, total RNA
of the four samples used for sequencing was extracted using a
mirVana Isolation kit (Ambion, Austin, USA) and 5 mg total RNA
was fractioned with a YM-100 Microcon centrifugal filter
(Millipore, Billerica, MA, USA). Small RNAs (,300 nt) were 39-
extended with a poly (A) tail by poly (A) polymerase and then Cy5
was ligated to the poly-A tails. In total, there were 533 customized
probes to detect novel miRNA candidate sequences; in addition,
28 sequences, including endogenous 5S rRNAs and artificially
synthesized single base mismatch probes, were added as positive
and negative controls, respectively. Each detection probe was run
in triplicate. Hybridization was carried out on a mParafloTM
microfluidic chip with 100 mL 6xSSPE buffer (0.90 M NaCl,
60 mM Na2HPO4, 6 mM EDTA, pH 6.8) at 34uC overnight
using a micro-circulation pump (Atactic Technologies, Houston,
TX, USA). Hybridization images were collected by using a laser
scanner (GenePix 4000B, Molecular Device, Sunnyvale, CA,
USA) and digitized by Array-Pro image analysis software (Media
Cybernetics, Bethesda, MD, USA). The signal values were derived
by background subtraction and normalization. A transcript must
have met at least three criteria to be considered detectable: signal
intensity.3x (background standard deviation), spot CV,0.5 (CV
was calculated by standard deviation/signal intensity), and at least
2 of 3 replicate probes were above detection level.
Analysis of Differentially Expressed miRNAs Based on
Counts in Deep Sequencing
miRNA differential expression based on deep-sequencing
counts was analyzed using a web tool, IDEG6 [28], http://
telethon.bio.unipd.it/bioinfo/IDEG6_form/. The Audic and
Claverie, Fisher exact test, and Chi-squared 262 test were all
conducted, and the significance threshold was set to be 0.001 in
each test. Bonferroni correction was applied as a correction for
multiple testing.
qPCR for Novel miRNA Candidate Verification and miRNA
Differential Expression
In total, confirmation of 17 novel miRNA candidates in
tumorous spleen and differential expression of nine known chicken
Table 4. Samples from three groups used in qPCR.
MDV-infected spleens MD lymphomas from livers Non-infected spleens
Sex Days post infection Sex Days post infection Sex Days post infection
Female 35 Female 31 Female 33
Female 36 Female 36 Female 38
Female 37 Female 37 Female 40
Female 38 Female 38 Female 42
Male 38 Male 40 Male 40
Male 46 Male 46 Male 40
Male 48 Male 48 Male 48
Male 55 Male 55 Male 55
doi:10.1371/journal.pone.0051003.t004
Analysis of miRNA Transcriptome in Lymphoma
PLOS ONE | www.plosone.org 10 November 2012 | Volume 7 | Issue 11 | e51003
miRNAs in 24 samples was performed by using a stem-loop RT-
PCR. The stem-loop RT primer, and regular forward and reverse
primers were designed (Table S13). Total RNA was isolated by
using the mirVana miRNA Isolation Kit (Ambion, Austin, USA).
Reverse transcription was performed in 25 mL total volume,
including RNA, 1 6 RT buffer, 50 nM stem-loop RT primer,
0.25 mM each dNTPs, 3.33 U/ml MultiScribe reverse transcrip-
tase and 0.25 U/ml RNase inhibitor. The optimum thermal
cycling parameters were 16uC for 30 min, 42uC for 30 min, 85uC
for 5 min. Real-time PCR reactions were performed in the ABI
7300 system (Applied Biosystems, Foster City, Calif., USA) in a
final volume of 15mL with 1mL of RT production, 1.5 mM
forward primer, 0.7 mM reverse primer, and 16PCR mix (Power
SYBRH Green PCR Master Mix, Applied Biosystems, US). The
optimum thermal cycling parameters included 95uC for 10 min,
40 cycles of 95uC for 15 s, 60uC for 1 min, 95uC for 15 s, 60uC for
30 s, and 95uC for 15 s. Each individual sample and no-template
control was run in triplicate, and the average critical threshold
cycle (Ct) was calculated. The PCR products were cloned by using
pMD-19T plasmid and DH5a and sequenced to ensure that the
correct miRNA were amplified. For differential expression of nine
known miRNA, 28 s was used as the internal reference gene [14].
The 22DDCt method was used to calculate relative gene expression
levels across the three groups. All analyses were performed using
GLM model of SAS (SAS Institute, Cary, NC).
Validation for Interaction of miRNAs and Predicted Target
Genes using Luciferase Reporter Gene Assays
A pmiR-RB-REPORTTM vector [78] (Ribobio Co., Guangz-
hou, China) was used for 39 UTR-luciferase reporter assays to
detect interactions of gga-miR-181a with MYBL1 and IGF2BP3,
gga-miR-26a with EIF3A, gga-miR-221 with BCL11B. The
TargetScan Human database 6.1 http://targetscan.org/was used
to identify miRNA binding sites. The gga-miR-181a mimic, gga-
miR-26a mimic, gga-miR-221 mimic and their corresponding
negative controls (Ribobio Co.) were transfected with pmiR-RB-
REPORTTM-target gene UTR or pmiR-RB-REPORTTM-target
gene mutated UTR. Reporter assays were conducted in triplicate
using 293T cells. Transfection was done according to the
manufacturer’s instructions for LipofectamineTM 2000 (Invitrogen,
Carlsbad, CA) with 50 nM mimic and 100 ng/mL reporter
plasmid.
Supporting Information
Figure S1 Results for novel miRNA candidate sequenc-
ing. Novel miRNA candidates were verified by qPCR in
tumorous spleens and amplicons were cloned and sequencing.
A–Q shows sequences of PN-cfa-miR-107_R+2, PN-xtr-miR-
23a_R+1, PN-xtr-miR-20b_R+1, PN-xtr-miR-214_R-4, PN-xtr-
miR-26_R+3, PN-tgu-miR-425-5p_R+1, PN-tgu-miR-1388, PN-
rno-miR-214_R+1, PN-xtr-miR-125b_L-1R+1, PN-hsa-miR-
150_12TC, PN-mmu-miR-1937a_L-1_18CT, PC597-5p,
PC556-3p, PC30-5p, PC495-3p, PC34-3p, and PC306-5p,
respectively. Sequences in red frames are miRNA candidates.
Sequences in blue frames are reverse complementary sequences of
novel miRNA candidates.
(TIF)
Table S1 Known chicken and MDV miRNAs detected in
four samples.
(XLS)
Table S2 isomiRs for known chicken miRNAs in four
samples.
(XLS)
Table S3 Novel chicken and MDV miRNA candidates
from subgroup1, 2, and 3 in four samples.
(XLS)
Table S4 Counts for novel 39 or 59-derived miRNA
candidates and their corresponding known miRNAs in
four samples.
(XLS)
Table S5 Novel miRNA candidate probes.
(XLS)
Table S6 Microarray signals and deep sequencing
counts for 276 probes.
(XLS)
Table S7 Seventeen miRNAs verified by qPCR.
(XLS)
Table S8 Differentially expressed miRNAs in MDV-
infected tumorous spleen analyzed by IDEG6.
(XLS)
Table S9 Differentially expressed miRNAs in MD
lymphoma analyzed by IDEG6.
(XLS)
Table S10 Differential expression analysis of miRNAs
in MDV-infected compared with non-infected samples
using IDEG6.
(XLS)
Table S11 Predicted targets of nine known chicken
miRNAs.
(XLS)
Table S12 Candidate target genes of miRNAs.
(XLS)
Table S13 Primers used in qPCR for seventeen miRNA
candidates and nine known miRNAs.
(XLS)
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